Skip to main content

Antidote 3 Rattler Antivenin

This page contains information on Antidote 3 Rattler Antivenin for veterinary use.
The information provided typically includes the following:
  • Antidote 3 Rattler Antivenin Indications
  • Warnings and cautions for Antidote 3 Rattler Antivenin
  • Direction and dosage information for Antidote 3 Rattler Antivenin

Antidote 3 Rattler Antivenin

This treatment applies to the following species:
Company: VetOne




Rattlesnake • Copperhead

Cottonmouth / Water Moccasin

Antidote 3 Rattler Antivenin Indications and Usage

This antivenin is shown to be effective against envenomation in canine and equine due to North American Crotalidae. Crotalidae refers to the Crotalinae subfamily (commonly named ‘Pit Vipers’) and includes cottonmouths/water moccasins, copperheads, and rattlesnakes. This antivenin includes antibodies against, among other Crotalidae, Mohave Rattlesnake Type A which is often considered to be the most lethal rattlesnake due to the presence of highly debilitating neurotoxin A, also known as ‘The Mohave Toxin.’

Use of this antivenin within 24 hours of snakebite neutralizes venom, decreases swelling, minimizes pain, and decreases temperature in canine and equine patients.


This antivenin is a whole-IgG molecule Crotalidae Polyvalent Antivenin. This antivenin contains antivenom (antibodies) collected from healthy horses immunized against Crotalus atrox (Western Diamondback Rattlesnake), Crotalus adamanteus (Eastern Diamondback Rattlesnake), Crotalus viridis viridis (Prairie Rattlesnake), and Crotalus scutalatus scutulatus (Mohave Rattlesnake Type A).

This antivenin is produced through a manufacturing process that combines antibodies from both hemolytic and neurotoxic venoms, resulting in a unique antivenom matrix.

Additionally, through a unique IgG formulation, This antivenin naturally supplements clotting factors and serum proteins that the recovering immune system is lacking due to envenomation.

Sodium citrate is used in the manufacturing process. This product does not contain any preservatives.

Each serial of this antivenin must pass release criteria by neutralizing specific units of viperine venom activity in a live murine model.

Dosage and Administration

Administer to effect intravenously using a filtered IV set over a 20-60 minute period. This product should be thawed quickly (2-5 minutes) in warm, not hot, water while agitating and should be administered immediately.

Do not allow product to be heated for an extended period (over 10 minutes) at risk of denaturing the product, potentially leading to reactions or impotency. See “WARNINGS AND PRECAUTIONS” section of the insert for more details.

One to two 50 ml doses will be sufficient in most cases regardless of body size (equine, small canine, large canine). Additional doses may be necessary on a case-by-case basis.

Factors to consider include the severity of envenomation, type and size of snake, and size of patient (the smaller the body of the victim, the more the venom to blood volume ratio increases).

Administer this antivenin as is, without reconstitution or dilution. Do not mix this product with other fluids. As with any antivenin, additional fluids and supplemental therapies can be used. This antivenin has been administered in conjunction with, prior to, or immediately after other fluids and no direct risk or contraindication to the patient has been reported. Use professional judgment.

The use of corticosteroids is controversial. Use professional discretion.

Restricted to use by or under the direction of a licensed veterinarian.


This antivenin is recommended for use in canines as young as 8 weeks old. This antivenin has not been evaluated in pregnant or lactating bitches.


This antivenin is safe to use at any age. No data is available for pregnant or lactating mares.


If you are unfamiliar with administering this antivenin, please feel free to contact the manufacturer’s technical support team ( or 877-769-2340) to ensure proper procedure is followed. Guidance videos are available on the manufacturer’s website,

If administration must be delayed after thawing, keep product at room temperature (60-80°F) until needed. Discard if product has been thawed longer than six hours. Do not place in an incubator.

Administer product at room or body temperature. If administering at body temperature, warm to body temperature just prior to administration to minimize the risk of denaturing the antivenin due to extended heat exposure. Extended heat exposure can cause product impotency or, in rare cases, anaphylaxis.

Every reasonable precaution has been taken to safeguard this product. While this serial has been reviewed and found to be safe, there is always the possibility, while rare, of adverse events.


Always check patient history for previous equine protein exposure or previous reaction to foreign protein biologics. The risk of anaphylaxis may increase if the patient has a history of intravenous infusion of equine blood products, such as, but not limited to antiserums like tetanus antitoxin or other antivenin administration. There is no guaranteed time frame to wait between equine protein exposures to prevent an adverse reaction. Antiequine immunoglobulins are created by the canine in response to receiving equine products and can cause adverse events with subsequent equine protein exposures if given at peak circulation of these anti-equine immunoglobulins.

Typically, waiting at least 9 months between separate envenomation treatments with this or any equine-based product decreases the risk of anaphylaxis due to canine anti-equine immunoglobulins. Within a single envenomation event, multiple units can be given safely for up to 10 days after first administration; do not administer new units past 10 days after the initial dose at the increased risk of anaphylaxis.

Administer slowly for the first ten minutes and monitor for signs of anaphylaxis (hypotension, respiratory distress, vomiting, diarrhea, angioedema, urticaria). If no immediate adverse response occurs, administration may resume at an IV fluid administration rate appropriate for the patient. Use professional judgment for each individual case; weigh the benefits of continuing antivenin treatment depending on case severity and history of the patient. In case of anaphylaxis, give epinephrine.

In rare cases, serum sickness (a type III hypersensitive reaction) may present 10-14 days after administration. This condition is unpredictable but should be treated with corticosteroids and antihistamines; it is not life threatening. Typical signs are fever, uticaria, lethargy, swollen lymph nodes, and painful joints. This is an underreported condition and should be reported to the manufacturer if this occurs. While the literature is silent in regards to canine serum sickness rates, this condition is well documented in human envenomation treatments. Based on industry feedback, we would expect <0.05% patients receiving this product to experience serum sickness post use of this product.


Administer slowly for the first ten minutes and monitor for signs of anaphylaxis (hypotension, respiratory distress, angioedema, urticaria). If this occurs, discontinue use for 5-10 minutes, then resume at a slower rate of infusion. If adverse reactions persist, discontinue use.


Approximately 1200 doses of this antivenin were distributed to 198 veterinarians with only 0.76% reporting adverse events in canine. Of these adverse events, clinical signs included uticaria, vomiting, diarrhea, hypotension, and change in respiratory rate). No delayed hypersensitivity or volume overload occurred in these documented cases. No equine adverse events were reported. While these results show a high safety rate, there is always a risk of an adverse event with any blood product.

Detailed clinical evaluation of this antivenin was performed by 17 veterinary clinics on 132 envenomated dogs and 34 envenomated horses. Licensed veterinarians at these clinics reported successful results with this antivenin in canine and equine patients presenting with mild to severe symptoms of envenomation at time of treatment. Of 132 canine patients, 93% survived envenomation following treatment with this antivenin. Of 34 equine patients, 100% survived envenomation following treatment with this antivenin.

Keep frozen below -5°C (23°F) until use.

This antivenin has passed QA purity tests and should not be reused or refrozen once opened.

As this product does not include any harmful preservatives, unused portions may be safely discarded in the trash.

This package is not returnable for credit or exchange.

Join MG Biologics’ pursuit of pharmacovigilance by reporting all adverse events to 877-769-2340 or


Manufactured by: Mg Biologics, Ames, IA 50014

VLN 614

Distributed by: MWI, Boise, ID 83705

Iss. 01/18

PCN 6101.01

Net Contents:



50 mL

V1 580500

Label Iss. 12/17

CPN: 1315255.1

Distributed by MWI Animal Health

3041 W. PASADENA DR., BOISE, ID, 83705
Customer Service:   888-694-8381
Toll-Free:   800-824-3703
THIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details.

Copyright © 2023 Animalytix LLC. Updated: 2023-02-28